College of Pharmacy
HelixTalk Episode #110 - Top 10 Updated Recommendations from the ADA Standards of Care 2020
Date posted: March 17, 2020, 6:00 am
In this episode, we summarize some of the most significant changes in the newest version of American Diabetes Association - 2020 Standards of Medical Care in Diabetes guidelines.
Key Concepts
- When initiating therapy for diabetes, early consideration of combination drug therapy (rather than adding medications in a step-wise fashion) can help to reduce treatment failure and provide greater, more durable benefits.
- Unless cost is a major barrier, insulin analogs (such as lispro or aspart) are preferred over other human insulins (such as insulin regular and insulin NPH).
- In patients with risk factors for ASCVD or with a history of an ASCVD event, heart failure, or chronic kidney disease, current guidelines recommend the use of a GLP-1RA (such as liraglutide) or an SGLT2 inhibitor (such as empagliflozin) regardless of A1C status.
- Among pediatric patients aged > 10 years with type II diabetes, liraglutide is now recommended as the next add-on therapy after metformin.
References
- ADA Standards of Medical Care in Diabetes - 2020. Diabetes Care. 2020;43(supplement 1):S1-S212.